ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
第一作者:
Jiani,Liu
第一单位:
Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
作者:
主题词
动物(Animals);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);细胞凋亡(Apoptosis);骨肿瘤(Bone Neoplasms);细胞周期(Cell Cycle);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);环氧化酶2(Cyclooxygenase 2);环氧化酶2抑制剂(Cyclooxygenase 2 Inhibitors);剂量效应关系, 药物(Dose-Response Relationship, Drug);减量调节(Down-Regulation);药物协同作用(Drug Synergism);女(雌)性(Female);G1期(G1 Phase);基因表达调控, 酶学(Gene Expression Regulation, Enzymologic);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);人类(Humans);小鼠(Mice);小鼠, 近交BALB C(Mice, Inbred BALB C);小鼠, 裸(Mice, Nude);骨肉瘤(Osteosarcoma);磷酰化(Phosphorylation);哌啶类(Piperidines);喹唑啉类(Quinazolines);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.18632/oncotarget.4179
PMID
26050198
发布时间
2022-03-25
- 浏览10

Oncotarget
21341-52页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文